What Latvian Biomedical Research & Study centre does

Latvian Biomedical Research & Study Centre (BMC), founded in 1993 and headquartered at Rātsupītes iela 1 k-1 in Riga, is Latvia's principal public biomedical research institution, employing 51–100 staff across three research divisions — Molecular Medicine, Biotechnology and Structural Biology, and Molecular Ecology and Biosystems — supported by five fee-for-service core facilities: the Genome Centre, Bioinformatics, Cell Biology and Microscopy, Laboratory Animal, and Recombinant Protein Biotechnology. Its technology stack spans genomics, transcriptomics, epigenomics, metabolomics, microbiome analysis, next-generation sequencing, single-cell RNA sequencing, spatial transcriptomics, NMR-based structural biology, and extracellular vesicle isolation/characterization. BMC was the first institution in Latvia to implement single-cell and spatial transcriptomics and houses the Latvian National Biobank (Valsts iedzīvotāju genoma datubāze, VIGDB) with over 38,000 participants, serving as the country's national biobank coordinator within BBMRI-ERIC and contributing to the Genome of Europe and EU Joint Action on Personalized Cancer Medicine (JA-PCM) networks.

BMC's customer base is organized into four vertical segments: academic and biomedical research institutions (primary), healthcare providers and hospitals, pharmaceutical and biotechnology companies, and government and public health agencies such as the Latvian Ministry of Health. Named institutional customers include the University of Latvia, Riga East University Hospital, and the broader network of Latvian hospitals for patient-derived sample collection, with international access mediated through BBMRI-ERIC, Instruct-ERIC, and EU Joint Actions. Revenue is generated through public research funding from the Latvian government and EU programmes (Horizon Europe, ERDF, BioPhoT), competitive grants (including the €30 million IntegroHEALTH digital twin award under EU Teaming for Excellence), and direct fee-for-service contracts for core facility usage; pricing is not publicly disclosed and is negotiated per project.

Recent strategic activity has centred on portfolio build-out: BMC operates the BioPhoT-funded FLUID-C liquid biopsy platform (EV-responsive fibroblast biosensors for cancer detection), EVBoost (electromagnetic stimulation module for hollow-fiber bioreactor EV production), and the SynGABA microbiome-guided synbiotic. On May 31, 2026 BMC merged with the Latvian Institute of Organic Synthesis (OSI) to form the National Institute of Research and Innovation (NIRI), consolidating the country's two highest-rated ('5' scientific rating) research institutions under a single governance structure supported by the Saeima's May 2026 Biobank Law.

Name

Latvian Biomedical Research & Study centre

Legal name

Latvijas Biomedicīnas pētījumu un studiju centrs

Website

https://biomed.lu.lv

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

51–100 employees

Short description

Latvian Biomedical Research & Study Centre (BMC) is a public biomedical research institute in Riga operating three research divisions, five fee-for-service core facilities, and the Latvian National Biobank (38,000+ participants), serving Latvian hospitals, the University of Latvia, EU consortia, and international researchers through BBMRI-ERIC, JA-PCM, and BioPhoT-funded translational projects.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Central Laboratory Services (Core Lab Operations) (HLAGAEAA), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Biomedical research services
• National biobank operations
• Genomic sequencing services
• Multi-omics analysis
• Translational medicine research

Headquarters

HQ city

Riga

HQ country

Latvia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain

Revenue model

1. Public research funding: BMC is a publicly funded research institution receiving core funding from the Latvian government and project-based grants from EU funding programmes including Horizon Europe, ERDF, and national research programmes such as BioPhoT. Revenue is generated through competitive grant acquisition, service fees from core facilities, and institutional support.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

The Latvian Biomedical Research and Study Centre (BMC) is a publicly funded biomedical research institution that conducts molecular biology, biomedicine, and biotechnology research across three research divisions (Molecular Medicine, Biotechnology and Structural Biology, and Molecular Ecology and Biosystems) and operates five core service facilities (Genome Centre, Bioinformatics, Cell Biology and Microscopy, Laboratory Animal, and Recombinant Protein Biotechnology). It hosts the Latvian National Biobank (VIGDB) with over 38,000 participants and provides fee-for-service access to next-generation sequencing, multi-omics analysis, structural biology, animal models, and recombinant protein production for academic and industry partners.

Product overview

The Latvian Biomedical Research and Study Centre (BMC) is a multi-disciplinary biomedical research institution operating as a platform-plus-service model. It comprises three main research divisions — Molecular Medicine, Biotechnology and Structural Biology, and Molecular Ecology and Biosystems — supported by five core service facilities (Genome Centre, Bioinformatics, Cell Biology and Microscopy, Laboratory Animal, and Recombinant Protein Biotechnology). The research portfolio spans from fundamental genetics and disease mechanism studies to applied product development. Notable named initiatives include the Latvian National Biobank (Valsts iedzīvotāju genoma datubāze, >38,000 participants), the BioPhoT multi-project platform funding biomedical innovation (including FLUID-C, EVBoost, and SynGABA), and the IntegroHEALTH digital twin project for disease and pollution forecasting. BMC positions itself as Latvia's leading biomedical research institution covering the full research cycle from sample collection to multi-omics analysis and clinical translation.

Differentiator

Problem solved

Functional benefit

Products and services

• Genome Centre (Genoma centrs)
• Bioinformatics Core Facility
• Cell Biology and Microscopy Core Facility
• Laboratory Animal Core Facility
• Core Facility of Recombinant Protein Biotechnology
• Latvian National Biobank (Valsts iedzīvotāju genoma datubāze)
• FLUID-C (Functional Liquid Biopsies for Cancer Detection)
• EVBoost (Extracellular Vesicle Production Boosting)
• SynGABA (Glutamine-guided synbiotic for microbiome-mediated GABA production)
• IntegroHEALTH Digital Twin

Quantifiable outcome

• National Biobank with 38,000+ participants supporting population-scale genomic and biomedical research
• +3 more outcomes

Named customers4 records

Segments4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

Partnerships

Eleven partnerships are on record, tiered core.

• European Molecular Biology Laboratory (EMBL)coreStrategic or Co-development Partner · 14 May 2026EMBL serves as the international scientific partner for the IntegroHEALTH project, contributing world-class expertise to the €30 million digital twin initiative. The project combines local research capacity with EMBL's molecular biology excellence to develop innovative solutions for disease and pollution forecasting.
• University of DundeecoreStrategic or Co-development Partner · 14 May 2026University of Dundee (UK) is an international collaboration partner in the IntegroHEALTH digital twin project, providing expertise alongside EMBL and Latvian partners to combine local research capacity with world-class international expertise, ensuring project sustainability and excellence.
• Institute of Food Safety, Animal Health and Environment 'BIOR'coreStrategic or Co-development Partner · 14 May 2026BIOR is a key Latvian partner in the IntegroHEALTH digital twin project, collaborating with BMC and Riga Technical University to develop the digital health model for disease and environmental pollution forecasting using wastewater monitoring and advanced data processing.
• Riga Technical University (RTU)coreStrategic or Co-development Partner · 14 May 2026RTU provides supercomputing infrastructure critical for the IntegroHEALTH digital twin project, enabling processing of massive amounts of data and complex simulations for disease outbreak and pollution risk forecasting across Latvia.
• Genome of Europe (GoE)coreStrategic or Co-development Partner · 14 January 2026BMC contributes to the Genome of Europe initiative, a major European genomics project aimed at creating a reference database for genetic research and personalised medicine across Europe. BMC's national biobank data supports this continental effort.
• Joint Action on Personalized Cancer Medicine (JA-PCM)coreStrategic or Co-development Partner · 14 January 2026BMC is the competent authority for JA-PCM in Latvia, a EU Joint Action bringing together 29 European countries and 140+ partner organisations to promote personalised cancer care across Europe. Vita Rovīte participated in the JA-PCM launch meeting in Brussels, January 2026.
• Instruct-ERIC (Integrated Structural Biology Infrastructure)coreStrategic or Co-development Partner · 1 January 2026BMC participates in Instruct-ERIC through the Instruct-LV national research site, providing access to structural biology infrastructure including NMR spectroscopy. The centre implements the Latvian National Partnership Plan for Instruct-ERIC and conducts staff training programmes with consortium partners.
• BBMRI-ERIC (Biobanking and Biomolecular Resources Research Infrastructure)coreStrategic or Co-development Partner · 1 January 2025BMC is the national coordinator for Latvia's biobanking network within BBMRI-ERIC, participating in the management committee, implementing the Latvian National Partnership Plan, and contributing to the European biobank directory and data access frameworks. Vita Rovīte serves as Head of the Latvian National Biobank and Latvian National Biobank Network Coordinator within this infrastructure.
• Latvian Institute of Organic Synthesis (OSI)coreStrategic or Co-development Partner · 1 January 2025OSI and BMC are merging to form the National Institute of Research and Innovation (NIRI) on 31 May 2026. The two institutions have held a joint conference, share the International Advisory Board, and collaborate extensively in structural biology, NMR, and biomedical research through the MR LATVIA Twinning project and other joint initiatives.
• Lithuanian University of Health Sciences – Neuroscience InstitutecoreStrategic or Co-development Partner · 1 January 2024Collaborative partnership with Prof. Rasa Liutkeviciene's research group on the Latvian-Lithuanian-Taiwanese project investigating the role of ryanodine receptors in neuroendocrine tumour development, including electrophysiological and molecular tumourigenesis mechanisms. Joint meetings and research exchanges conducted at BMC.
• Taiwanese research partnerscoreStrategic or Co-development Partner · 1 January 2024Tripartite collaboration with Lithuanian and Taiwanese researchers on ryanodine receptor research in neuroendocrine tumours, with joint experiments and knowledge exchange conducted as part of the Latvian-Lithuanian-Taiwanese research project.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Estonian Biobank (University of Tartu): The Estonian national biobank at the University of Tartu, holding ~200,000 participant genotypes and operating as a national coordinator within BBMRI-ERIC. Directly comparable to BMC's VIGDB by mandate, scale of population genomics, and Baltic region positioning.
• Latvian Institute of Organic Synthesis (OSI): Latvian research institute specializing in medicinal chemistry and drug design, BMC's merger partner forming NIRI in May 2026. Directly comparable in national mandate, headcount, and grant-funding model, and now structurally integrated with BMC.
• Lithuanian University of Health Sciences – Neuroscience Institute: Lithuania's leading biomedical research university with active Baltic collaboration with BMC (e.g., neuroendocrine tumor ryanodine receptor research). Comparable in regional scope, translational research focus, and EU grant dependency.
• Institute of Food Safety, Animal Health and Environment 'BIOR': Latvian public research institute partnering with BMC on the IntegroHEALTH digital twin project. Comparable as a Latvian publicly-funded life science research organization with overlapping genomics, metagenomics, and public-health surveillance mandates.

Broad incumbents

• FinnGen: Large-scale Finnish genomics initiative combining national biobank data with hospital-based cohorts and pharma partnerships. Comparable to BMC in national-coordinator model and BBMRI-ERIC participation, but materially larger and more commercially developed.
• Karolinska Institutet: Sweden's premier biomedical research university, hosting major national biobanks and precision medicine programs. Comparable to BMC in scientific mandate and EU network participation, but operates at vastly greater scale, funding, and international standing.
• European Molecular Biology Laboratory (EMBL): Intergovernmental molecular biology research organization partnering with BMC on the IntegroHEALTH digital twin project. Comparable in molecular biology focus and EU grant-funded model, but operates globally with significantly larger infrastructure and budget.
• Wellcome Sanger Institute: UK-based genomics and bioinformatics powerhouse with deep ties to UK Biobank and large-scale population sequencing programs. Comparable to BMC in genomics and bioinformatics capability, but with substantially greater funding and global commercial reach.
• Institute of Molecular Life Sciences (University of Zurich): Swiss university-based molecular life sciences research institute conducting multi-omics and disease mechanism research. Comparable to BMC in research scope (genomics, transcriptomics, structural biology) and academic governance, but with materially higher funding base.

Regional players

• Oslo University Hospital – Department of Research and Innovation: Norway's largest hospital-integrated research environment with national biobank coordination and BBMRI-ERIC participation. Comparable to BMC in translational biomedical research and biobanking, but operating in a higher-income Nordic funding context.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/BMC_LV
• YouTubeyoutube.com/channel/UCrtISzYHCP104XYe5iQuhpw
• Facebookfacebook.com/LatvianBiomedicalCentre
• LinkedInlinkedin.com/company/latvianbiomedicalresearchandstudycentre

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Latvian Biomedical Research & Study centre